secwatch.observer — SEC 8-K summary
======================================

Issuer:     20/20 Biolabs, Inc. (AIDX)
CIK:        0001139685
Form:       8-K
Filed at:   2026-05-20T20:10:53+00:00
Accession:  0001213900-26-059526
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

20/20 BioLabs Q1 revenue $0.4M, net loss $2.2M; expects Q2 rebound from firefighter programs
--------------------------------------------------------------------------------

- Q1 revenue $0.4M vs $0.6M YoY; net loss $2.2M vs $0.8M; gross margin 17.8% vs 29.9%.
- Cash $4.2M (vs $1.0M Dec 2025) after $5M private placement; deferred revenue $0.5M.
- State-funded firefighter cancer screening programs expected to drive meaningful Q2 revenue; second state committed.
- Launched OneTest for Longevity with IBM; exclusive U.S. CKD license from ROKIT Healthcare.
- Medicare MCED Screening Act signed Feb 2026; pathway for Medicare coverage by 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026059526/0001213900-26-059526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026059526/ea0291642-8k_2020bio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-059526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer